Related references
Note: Only part of the references are listed.Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gerard Zalcman et al.
LANCET (2016)
Pleurodesis outcome in malignant pleural mesothelioma
Edward Thomas Hamilton Fysh et al.
THORAX (2013)
Ovarian cancer ascites protects from TRAIL-induced cell death through αvβ5 integrin-mediated focal adhesion kinase and Akt activation
D. Lane et al.
ONCOGENE (2010)
Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010
Clare Hooper et al.
THORAX (2010)
A Central Role for Tumor-derived Monocyte Chemoattractant Protein-1 in Malignant Pleural Effusion
Georgios T. Stathopoulos et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells
Denis Lane et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro
Chun-Chi Liang et al.
NATURE PROTOCOLS (2007)
Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion
H-H Yeh et al.
ONCOGENE (2006)
Clonogenic assay of cells in vitro
Nicolaas A. P. Franken et al.
NATURE PROTOCOLS (2006)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Vascular endothelial growth factor level correlates with transforming growth factor-β isoform levels in pleural effusions
DS Cheng et al.
CHEST (2000)
Share Paper
